# The role of hydrogen in the prevention and treatment of coronary atherosclerotic heart disease.
> 冠動脈アテローム性心疾患における水素の役割：炎症・糖脂質代謝への影響と分子メカニズムのレビュー


## Abstract

Coronary atherosclerotic heart disease (CHD), driven by chronic inflammation and oxidative lipid deposition, represents a major cardiovascular burden. This review examines the potential of molecular hydrogen (H₂) to counteract CHD-related pathology through multiple mechanisms. H₂ is reported to modulate inflammatory signaling via the NF-κB pathway, pyroptosis, mitophagy, endoplasmic reticulum stress, and the Nrf2 antioxidant pathway. In parallel, H₂ may normalize glycolipid metabolism through PI3K and AMPK signaling, thereby potentially limiting CHD progression. The review systematically outlines CHD pathogenesis, evaluates available evidence on H₂ efficacy, and proposes mechanistic hypotheses intended to guide future experimental and clinical investigations.

### Mechanism

H₂ is proposed to suppress CHD-related inflammation by modulating NF-κB, pyroptosis, mitophagy, and ER stress pathways, while improving glycolipid metabolism via PI3K and AMPK signaling, with additional antioxidant effects mediated through Nrf2 activation.

## Bibliographic

- **Authors**: Chen Y, Wei Y, Tang W
- **Journal**: Eur J Pharmacol
- **Year**: 2024 (2024-06-05)
- **PMID**: [38615891](https://pubmed.ncbi.nlm.nih.gov/38615891/)
- **DOI**: [10.1016/j.ejphar.2024.176586](https://doi.org/10.1016/j.ejphar.2024.176586)
- **Study type**: review
- **Delivery route**: not specified
- **Effect reported**: not assessed

## Delivery context

The delivery route is not clearly identifiable from this paper. For hydrogen intake, inhalation is the most efficient route; inhalation, however, carries explosion risk (empirical LFL of 10%; high-concentration devices are not recommended).

## Safety notes

The delivery route is not clearly identifiable from this paper. For hydrogen intake, inhalation is the most efficient route; inhalation, however, carries explosion risk (empirical LFL of 10%; high-concentration devices are not recommended).

See also:
- [Inhalation concentration and LFL / UFL](https://h2-papers.org/en/safety-notes/inhalation-concentration)
- [Consumer Affairs Agency accident cases](https://h2-papers.org/en/safety-notes/accident-cases)

---

> **Cite as**: H2 Papers — PMID 38615891. https://h2-papers.org/en/papers/38615891
> **Source**: PubMed PMID [38615891](https://pubmed.ncbi.nlm.nih.gov/38615891/)